BioCentury
ARTICLE | Strategy

Leading by example

Why Novartis may adopt indication-based pricing for Kymriah

January 11, 2018 9:25 PM UTC

A third-party cost-effectiveness analysis of CAR T therapies Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel suggests that Novartis AG may need to price Kymriah differently for its second indication. Fortunately, the pharma is already discussing such a plan with payers.

In a draft report issued on Dec. 19, the Institute for Clinical and Economic Review (ICER) concluded that both Kymriah and Gilead Sciences Inc.’s Yescarta are priced in line with their long-term benefits in the indications for which they are approved...